Siemens at ECCMID 2013–Booth #609
Maximize Workflow Efficiency.
Shaping the future of healthcare together.
Siemens Healthineers portfolio of molecular and immunoassay testing systems offer a total solution for the effective treatment and management of a wide range of infectious diseases. Learn about the Atellica MDX 160 Molecular System1, a flexible molecular diagnostics platform that offers one solution and more choice for Siemens assays as well as other manufacturers’ assays and laboratory-developed tests.
Fast Track Diagnostics Products.
Explore our latest molecular solutions for infectious disease testing using the syndromic approach. Meet our experts and learn more about our growing menu of real-time PCR multiplex kits for viruses, bacteria, fungi, and parasites.
In our booth, you will have the opportunity to view our latest molecular solutions, including the Atellica® MDX 160 Molecular System, NEW Fast Track Cycler2, NEW Artificial Intelligence based FastFinder™ software for PCR analysis3, and NEW Fast Track Diagnostics menu of infectious disease assays4.
Atellica MDX 160 Molecular System
The Atellica MDX 160 Molecular System: A powerful automation solution that provides flexibility and highly accurate results for a broad range of molecular tests, including HIV, HBV, HCV, CT/GC, Immunosuppression, and more.
The Atellica MDX 160 Molecular System is a flexible, automated molecular system that delivers maximum productivity to your laboratory. The new system has a growing IVD menu, including other manufacturers’ assays and laboratory-developed tests (LDTs), and supports extraction of nucleic acids from multiple sample types.
Our proprietary extraction technology and open-channel system gives laboratories the flexibility to develop their own protocols for extraction, amplification, and detection of nucleic acids from a wide variety of targets. The innovative Atellica MiPLX Software Solution enhances workflow by automating extraction and PCR plate set-up as well as enabling simultaneous testing of up to six assays per run from a single patient sample. New tailored dynamic configurations further enhance flexibility and workflow efficiency by offering a range of testing protocols and fully-tailored workflows. With the new Siemens system, users can now choose from a variety of testing strategies including: flexible multiplex testing, PCR plate set-up or nucleic acid extraction.
The Atellica MDX 160 Molecular System combines the performance, easy-to-use automation, and small footprint of the Atellica MDX 160 Sample Prep and the Applied Biosystems™ QuantStudio™ 5 DX Real-time PCR Instrument*. The user-friendly system reduces manual labor, allowing personnel to spend time on other value-added activities, while providing outstanding assay performance and choice with a broad IVD menu.
Experience the power of a revolutionary diagnostic system engineered to deliver control and simplicity, so you can drive better outcomes.
Learn more about the Atellica MDX 160 Molecular System
Learn more about our molecular IVD assays (Fast Track Diagnostics Assays Now Available!)
Learn more about VERSANT HCV Genotype 2.0 Assay (LiPA) (Now FDA-approved in the US!)
*Applied Biosystems and QuantStudio are trademarks of Thermo Fisher Scientific Inc. RUO available in the US.
ATELLICA and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners. Product availability may vary from country to country and is subject to varying regulatory requirements.
1. Under development. Not for sale. Atellica is a registered trademark of Siemens Healthcare Diagnostics Inc.
2. For research use only in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements
3. For research use only in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements
4. FTD assays CE-marked in the EU. For research use only in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements